Telix (ASX:TLX) share price charges higher on FDA update

The Telix Pharmaceuticals Ltd (ASX:TLX) share price is charging higher on Thursday after releasing an update on its FDA submission for TLX591-CDx…

| More on:
Biotechnology graphics

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market may be dropping lower today but that hasn't stopped the Telix Pharmaceuticals Ltd (ASX: TLX) share price from charging higher.

In morning trade the biopharmaceutical company's shares are up 3.5% to $1.82.

Why is the Telix share price charging higher?

Investors have been buying Telix's shares on Thursday after it provided an update on its TLX591-CDx product.

TLX591-CDx is a proprietary formulation of PSMA-11, a novel imaging agent targeting prostate-specific membrane antigen (PSMA). It was originally developed by the Heidelberg group of the Deutsches Krebsforschungszentrum.

The cold kit format of TLX591-CDx enables rapid radiolabelling at room temperature with high radiochemical purity and production consistency, optimised for the radiopharmacy setting.

What was today's update?

This morning Telix revealed that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for TLX591-CDx.

This NDA submission includes clinical data from over 600 patients obtained from both prospective and retrospective clinical studies. It also builds on definitive peer-reviewed clinical research conducted at leading academic centres. These include the University of California, the Peter MacCallum Cancer Centre in Australia, and the Heidelberg University Hospital in Germany.

A significant milestone.

Telix USA President, Dr Bernard Lambert, commented: "We are pleased to have achieved this significant milestone with the submission of the first commercial NDA for PSMA imaging in the United States."

"Telix has engaged with the FDA since July 2019, with valuable guidance resulting in what we believe to be a comprehensive submission. Subject to FDA approval, we look forward to bringing this product to market with our commercial partners to serve the needs of men living with prostate cancer," he added.

Telix's CEO, Dr Christian Behrenbruch, believes this submission is a "major commercial inflection point" for the company.

"The Telix team and our advisors have done an outstanding job of preparing this submission, which we believe is founded on compelling clinical evidence that supports broad diagnostic utility in the management of prostate cancer," Dr Behrenbruch concluded.

No date has been given for when an FDA decision is likely to be announced.

Motley Fool contributor James Mickleboro owns shares of TELIXPHARM DEF SET. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Two smiling work colleagues discuss an investment or business plan at their office.
Share Gainers

Why 4DMedical, Boss Energy, Syrah, and Vulcan shares are charging higher today

Let's see why these shares are starting the week on a high.

Read more »

Three happy multi-ethnic business colleagues discuss investment or finance possibilities in an office.
Financial Shares

The IAG share price soared 50% in 2024! Here's how

IAG shares smashed the benchmark returns in 2024. But how?

Read more »

Best Shares

Which ASX 200 large-cap shares outperformed their peers in 2024?

We reveal the 16 best ASX 200 large-cap stocks for share price growth last year.

Read more »

Three happy girls on jumping motion with inflatable mattresses at the beach.
Share Gainers

3 ASX All Ords shares leading the charge in 2025

These ASX All Ords shares have soared 16% to 37% already in 2025.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Insignia, Rio Tinto, St Barbara, and Structural Monitoring shares are rising today

These shares are ending the week on a positive note. But why? Let's find out.

Read more »

A boy stands firm on a rocky cliff holding a rocket in each hand and looking up toward the sky, anticipating flying into space.
Small Cap Shares

2 ASX small-cap shares rocketing 35% to 54% today

Two soaring ASX small-cap shares are setting the bar high on Friday.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Arcadium Lithium, Bellevue Gold, Catalyst Metals, and Northern Star shares are rising today

These shares are having a good session on Thursday. But why? Let's find out.

Read more »

A group of people at a party look upwards to the camera as they celebrate the rise of ASX value shares
Share Gainers

16 ASX shares that doubled in value last year

There were multiple ASX All Ords stocks that delivered double-or-more share price growth in 2024.

Read more »